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1. Introduction 
Infectious diseases have been a major global cause of morbidity and mortality for 
thousands of years. Control of infectious diseases has largely been influenced by 
the establishment of a new consciousness for hygiene by Semmelweiß in the 19th 
century. Public health education and vaccination programs were developed and 
environmental hygiene and pasteurization gained more and more importance. 
Apart from such prevention, effective treatment of infectious diseases became 
possible in the beginning of the 20th century with the discovery of Penicillin. The 
development of other antibiotic agents followed in the beginning of the 20th 
century (1). Nowadays, numerous potent antibiotic substances such as 4th and 
5th generation cephalosporines, carbapenemes or glycylcyclines with broad 
spectrum of action are available (2).  
Unfortunately, during the last decades these substances lost power: the problem 
of drug-resistant bacteria has emerged and is gaining importance. Whenever an 
antibiotic is used, it puts selective pressure on microorganisms, eradicating only 
the susceptible strains. Therefore, the emergence of antimicrobial resistance 
occurs as a direct consequence of the extensive use and particularly misuse of 
antibiotics. Globalization, international travel and trade allow resistant strains to 
pass borders and spread with an alarming speed. Prominent examples for 
resistant bacteria are methicillin resistant staphylococcus aureus (MRSA) or 
multidrug resistant gram negative bacteria (MRGN). 
Infectious diseases, easily treated a few years ago, may now have no treatment 
option, if the causative organism does not respond to the antibiotic therapy 
anymore.  
Environments with sick or immunocompromised patients and extensive antibiotic 
use such as hospitals or healthcare facilities are a source of multi-resistant 
bacteria (3).This leads to a higher risk of healthcare associated infections (HAI) 
for hospitalized patients, particularly for critically ill patients, patients of older age 
or children. 
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Critically ill children are at high risk for severe HAI due to invasive devices and 
procedures, secondary immunosuppression and underlying diseases. 
Consequently, nosocomial infections with drug-resistant organisms have become 
a serious concern for children admitted to the paediatric intensive care unit 
(PICU) and will supposedly increase in the next years (4,5).  
1.1 Multidrug resistant gram-negative organisms 
During the last decades, nosocomial infections caused by multidrug resistant 
organisms (MDR) have mainly been gram-positive, first of all MRSA. However, 
since the beginning of the 21st century, MDR gram-negative organisms have 
gained an increasing importance as a cause for nosocomial infections (6). 
Amongst these gram-negative bacteria, the family of Enterobacteriaceae is of 
particular concern. In hospitals, Enterobacteriaceae are amongst the most 
important causative organisms for various nosocomial infections such as 
bloodstream infections, pneumonia, urinary tract infections, surgical site 
infections, or rarely meningitis (7,8).  
Enterobacteriaceae are facultative anaerobic organisms, including bacterial 
genera such as Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter and 
Proteus. These bacteria are a physiological part of the enteric system but can 
also cause different infections in healthy and especially in immunocompromised 
patients. Furthermore, Yersinia and Salmonella are part of the 
Enterobacteriaceae, those genera are not physiologically found in the human 
enteric system and are obligate pathogens (8). 
1.2 Emerging antibiotic resistance 
During the last years, a trend of increasing drug resistance in gram-negative 
organisms has been observed worldwide for several reasons: hospitals use 
antibiotics frequently and some complicated cases require a prolonged or even 
permanent antibiotic treatment. These therapies put bacteria under selective 
pressure and lead to the development of resistance (3,9). MDR organisms might 
as well have been brought into the hospitals from other environments: patients 
admitted from other hospitals, care facilities, or high prevalence countries might 
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be colonized with MDR bacteria (10). Furthermore, the resistant bacteria may be 
transmitted by doctors, nurses, from patient to patient or by visitors (11).  
This worldwide trend is alarming, considering the fact that not only screening and 
prevention, but also the development of new antimicrobial drugs has focused on 
gram-positive organisms during the last years, leaving only few antibiotics to fight 
MDR gram-negative infections (6,12).  
A striking example is the spread of carbapenem-resistant Klebsiella pneumoniae 
in Europe. Introduced in the 1980s, carbapenemes used to be the last-line 
antibiotics against MDR gram-negative infections. Their chemical structure led to 
a broad spectrum of activity and a very slow hydrolization by common bacterial 
beta-lactamases. However, the emergence of carbapenemases, beta-
lactamases that hydrolyse carbapenemes, leads to inefficiency of these drugs 
against carbapenemase-producing bacteria (12). Treatment options for patients 
infected with carbapenem-resistant K.pneumoniae or other carbapenem-
resistant bacteria are limited. Unfortunately, the European centre for disease 
control (ECDC) reports an increasing percentage of carbapenem-resistant 
K.pneumoniae in the European Union since 2009 (10).These data are similar to 
observations in the U.S. and other countries, that report spread and local 
outbreaks of carbapenemase-producing bacteria since the beginning of the 
century (10).  
Apart from K.pneumoniae, especially A.baumanii and P. aeruginosa became 
resistant to several common antibiotic regimens (13). In consequence many first 
line-antibiotics are by now without effect against these organisms. Older drugs 
with wider spectrum and higher toxic potential have to be used to treat infections. 
Furthermore, empiric antibiotic treatment often fails when drug resistant 
organisms are the cause of infection. Therefore, infection with drug resistant 
organisms is potentially associated with higher mortality compared to infection 
caused by susceptible organisms (12). 
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1.3 Mechanisms of drug resistance 
Resistances against antibiotics can be intrinsic i.e. the organism has a primary 
resistance against a class of antibiotics. An example is Mycoplasma, a bacillus 
without a cell wall. Consequently, it is intrinsically resistant to all β-lactam-
antibiotics which inhibit the building of a cell-wall. Extrinsic resistances are 
caused by mutation of genes or by virus-plasmid transfer of resistance-genes 
from one bacillus to another, even between different species.   
The most common mechanisms of gaining resistances in bacilli are:  
1. β-lactamases:  The most frequent mechanism is the expression of the enzyme 
β-lactamase that can inhibit several antibiotic agents by hydrolysing their β-
lactam-structures. β-lactamases are a heterogeneous group of molecules, 
differing in genetics, molecular structure, substrates and possibilities to be 
inhibited. A highly important group are the Extended-Spectrum-β-Lactamases 
(ESBL) that cause resistances against penicillins, cephalosporins, monobactams 
and oxyimino-cephalosporins. K.pneumoniae and recently increasingly E.coli are 
the most frequently isolated ESBL-producers (14). Lately, more and more gram-
negative organisms, especially E.cloacae express Carbapenemases, ß-
lactamases that lead to resistance against carbapenemes (15). In Citrobacter 
freundii and Morganella morganii a higher expression of the intrinsic AmpC-β-
Lactamase causes a resistance against cephalosporins and penicillins. In case 
of high concentrations of this enzyme, even special lactamase-inhibitors are not 
sufficient to inhibit the AmpC-β-Lactamase (16).  
2. Changes in the binding-side of antibiotics:  Mutations of the bacterial 
enzymes Gyrase and Topoisomerase IV impede the binding of antibiotics, e.g. 
fluorchinolones. These mutations are often transmitted by plasmids (17).   
3. Changes in the membrane: Mutations in genes coding for certain membrane-
proteins can lower the permeability of the bacterial cell-membrane for certain 
antibiotics. This mechanism is often found in ESBL-producing E.coli and P. 
aeruginosa (18).  
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4. Active efflux: Chromosomal mutations can lead to the production of 
transporting-proteins that remove antibiotics from the cell before they can unfold 
their effects. P. aeruginosa and A. baumanii are the most frequently reported 
bacteria with active efflux. 
As mechanisms of resistance are highly variable, the diagnosis of drug-
resistance and development of new antimicrobial drugs are difficult (19). Empiric 
antibiotic therapy without availability of cultures and sensitivities, or a therapy that 
is not adapted to the resistance-profile, can lead to selection of resistant 
organisms. Inefficency of antibiotic treatment against resistant clones of bacteria 
leads to overgrowth of the resistant clones, while the susceptible ones are 
suppressed by the treatment. 
1.4 Risk of healthcare associated infections due to MDR organisms 
Especially in PICUs, children are at a high risk for nosocomial infections. HAI are 
a particular threat due to physiological immaturity of the immune system in early 
stages of a child’s life, severe underlying diseases, invasive procedures or 
secondary immuno-suppression (e.g. corticosteroid treatment, chemotherapy). In 
German PICUs gram-negative organisms are amongst the most frequently 
isolated organisms causing HAI onset (7,20). MDR organisms in particular are 
responsible for an increasing part of HAI on PICUs, differing between nations (16-
31%) and hospitals (21,22). 
Gram-negative bacteria elicit different types of nosocomial infections; 
bloodstream infections, respiratory infections, especially ventilator-associated 
pneumonia (VAP), surgical site infections and urinary tract infections are the most 
common ones. If these infections are caused by multi-resistant strains, treatment 
becomes challenging. Even though MDR organisms are not necessarily more 
pathogenic than susceptible ones, infections with resistant bacteria have a worse 
outcome. They lead to more complications, longer hospitalization, higher 
mortality and higher healthcare-costs (9). This worse outcome can be explained 
by the ineffective empiric therapy and the delay of appropriate antibiotic treatment 
(12).  
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The risk of infection with MDR gram-negative bacteria increases in several 
circumstances. Predisposing factors for MDR infections depend on the 
environment and the individual treatment of a patient. Immunosuppression, 
severe underlying disease, long hospitalization, catheterization and gastral 
intubation increase the risk of MDR infection just as previous antibiotic treatment, 
living in long term care facilities, staying in endemic areas or contaminated food 
(E.coli) (23-25). Robert E. et al reported an ESBL-rate on intensive care units 
(ICUs) twice as high as on normal wards (26). In children, premature birth, low 
age and female sex are additional risk factors for HAI due to gram-negative 
bacteria (21,27) 
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1.5 Screening and prevention of infection with multidrug resistant 
organisms 
Children admitted to PICU from long term care facilities and with multiple previous 
hospitalizations should screened for bacteria and resistances, including MRSA 
and Vancomycin-resistant Enterococci (VRE) on admission. Particular screening 
guidelines for PICUs do not currently exist. However, screening can be based on 
the definition of multidrug resistant gram-negative bacteria recommended by the 
German Robert-Koch-Institute (RKI) and the RKI guidelines for NICUs (16,28). 
The RKI definition is based on four major classes of antimicrobial substances: 
acylureidopenicillins, 3rd/4th generation cephalosporins, carbapenemes and 
flourchinolones. Depending on the number of resistances, bacteria are defined 
as 3 or 4 MRGN. Taking into account that an empiric therapy with flourchinolones 
is contra-indicated in children, the RKI has subjoined the category 2 MRGN Neo-
Päd for paediatrics and neonatology. 
In case of a positive screening result, isolation precautions are warranted 
according to local/national hygiene guidelines or the RKI recommendation 
(16,29). 
Contact precautions (single room, hand hygiene, single use gloves and coats) 
are mandatory in patients tested colonized with a 4 MRGN organism. In case of 
colonization of the respiratory tract, droplet precautions (surgical facemask) are 
necessary as well.  
In a PICU setting, precautions for 3 MRGN and 2 MRGN Neo-Päd bacteria are 
the same as for 4 MRGN bacteria because the setting bears a higher risk for 
MRGN infection. 
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1.6 VAP on PICU 
1.6.1 Ventilator-associated pneumonia 
Ventilator-associated pneumonia is one of the most common nosocomial 
infections in critically ill children (7,30). VAP is a severe complication, occurring 
in 3-17% of ventilated PICU patients (31,32). The overall onset of VAP differs 
between 7.02-11.6/1000 ventilator-days (33,34). Children on mechanical 
ventilation are often critically ill, sedated and unable to communicate. Therefore, 
it can be difficult to diagnose a VAP, especially if younger children present with 
comorbidities or unspecific clinical symptoms. The American centre for disease 
control (CDC) has defined a set of criteria to diagnose VAP. The criteria include 
radiographic, clinical and microbiological findings (34). Even though the CDC 
definition for the diagnosis of VAP is commonly accepted, the criteria of VAP-
diagnosis are not well established and differ between hospitals. The CDC 
definition is criticised for the requirement of radiographic evidence since the 
interpretation and language used to describe the findings is subjective and may 
differ between institutions. Furthermore, subjectivity of some clinical diagnostic 
criteria as well as variability in specimen collection and culturing practices may 
affect case-finding (35). However, the guidelines are widely established and can 
help to improve internal quality purposes (36). It is well known that VAP leads to 
prolonged ventilation, hospitalization and higher mortality (14%-76%) of the 
ventilated child (30,31,37,38). 
1.6.2 Causative organisms for VAP 
MDR Enterobacteriaceae have become a particular concern for mechanically 
ventilated patients (39). Placement of an endotracheal tube is followed rapidly by 
tracheal colonization with potentially pathogenic microorganisms from the 
oropharyngeal flora, including MDR organisms (40,41). During the last years, 
gram-negative bacteria were the most frequently isolated pathogens in VAP-
PICU-patients in Germany and in the US (42-68%) followed by S. aureus (15-
20%) and Haemophilus influenza (11%) (4,42). One third of all VAPs are caused 
not only by a single, but by different species at the same time (42).The high 
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prevalence of gram-negative bacteria in ventilated patients might be aggravated 
by the fact that in critically ill patients the oropharyngeal colonization can shift 
from gram-positive to gram-negative specimens (43).This shift could be caused 
by the use of antibiotics that suppress the normal intestinal and oropharyngeal 
microflora which is gradually replaced by Klebsiella spp, Enterobacter spp, 
Serratia spp and other gram-negative bacteria (44).  Oropharyngeal bacteria can 
be transferred to the lower respiratory tract during intubation and cause severe 
infections thereafter. 
In adults, gram-negative organisms, especially Pseudomonas, Klebsiella and 
E.coli are the most common pathogens causing VAP. Several studies report an 
increasing rate of drug resistance amongst these causative organisms: an 
Australian adult ICU reports 29% MDR of all isolates causing VAP, a Belgium 
adult ICU observed 21% of all gram-negative organisms causing VAP were MDR 
(45,46). From countries with lower medical and hygienic standards much higher 
MDR rates have been reported (47). 
Gram-negative organisms are most likely to cause VAP in PICU patients (48). If 
MDR gram-negative organisms become more prevalent, it may well be that MDR-
rates in PICU VAP rise as well. An analysis from a PICU in Shanghai supports 
this hypothesis by reporting that most of the gram-negative bacteria causing VAP 
were resistant (38). 
1.6.3 Risk factors for VAP on PICU    
Several different risk factors for VAP have been detected in various studies during 
the last years. The results partially differ or are even contradictory. Depending on 
the study, the PICU/NICU (neonatal intensive care unit) length of stay, duration 
of mechanical ventilation, previous antibiotic or steroid therapy, tracheostomy, 
genetic syndromes, bloodstream infection, emergency intubation, re-intubation, 
previous bronchoscopy, age <1 y, long term sedation, colonization of the upper 
respiratory tract, previous surgery, both enteral and parenteral nutrition, 
transfusion, female gender and discontinuous PICU-stay have been declared as 
risk factors (30,32,42,49-51). 
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In a meta-analysis from 2013, B. Liu et al. extracted significant and independent 
risk factors for VAP in ventilated children, which were genetic syndromes, re-
intubation and accidental extubation, bloodstream infections, previous treatment 
with antibiotics or steroids and bronchoscopies (42). A factor that has not been 
mentioned in this analysis, but seems to be important too, is the duration of 
ventilation - prolonged ventilation also increases the risk of VAP (45,50).  
1.6.4 Prevention, screening and treatment of VAP 
Cooper et. al propose a bundle of prevention methods especially for VAP in 
children (52): 
• Elevated head of the bed 
• Hand hygiene before and after contact with patient or ventilator 
• Providing oral hygiene according to the patients age 
• Change ventilator circuit every 7 days or when circuit is visibly soiled or 
malfunctioning 
• Suction endotracheal tube only when indicated by a clinical examination; 
do not instil physiological saline for suctioning 
• Drain condensation from ventilator circuit every 2-4 hours 
 
The current guidelines recommend quantitative cultures from material of the 
lower respiratory tract to diagnose a nosocomial pneumonia (53). Tracheal 
aspirate (TA) or bronchoalveolar lavage (BAL) can be used to screen patients for 
MDR-bacteria in the lower respiratory tract. 
However, a positive screening result on MDR-bacteria in tracheal aspirate does 
not necessarily imply an infection. Infection rates in colonized patients are 
reported up to 33% (E.coli) and more than 50% (Pseudomonas spp) depending 
on species and patient population (16). 
Furthermore, neither tracheal aspirate nor BAL are 100% sensitive or specific 
and can lead to false treatment and antibiotic overuse (54,55). A lung biopsy 
would provide the most accurate results to diagnose VAP. However, as lung 
biopsy is a highly invasive procedure, clinical CDC criteria in combination with 
tracheal aspirate or BAL are far more adequate in clinical practice. 
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Current treatment guidelines for VAP-prevention mostly refer to VAP in adults 
and recommend empirical coverage of gram-negative bacilli with a third or fourth 
generation cephalosporin, piperacillin-tazobactam or a carbapenem in 
combination with a fluoroquinolone or an aminoglycoside, based on the local 
patterns of susceptibility. In many cases colistin or tigecyclin are the only 
treatment options (56). However, tigecyclin is not licensed for the treatment of 
pneumonia and contra-indicated for children under 8 years and thus must be 
used off-label. The same limitations apply to flourqinolones; they are also 
contraindicated in children  (57). 
1.7 Aims of the study 
Children admitted to a PICU have a high risk for severe HAI with all possible 
consequences. These may be elevated morbidity and mortality, longer 
hospitalization and higher healthcare costs. Amongst gram-negative organisms, 
MDR Enterobacteriaceae are becoming more dominant in intensive care 
medicine and rise concern in ventilated paediatric patients due to limited 
therapeutic options. 
The present study aims: 
1. (a) to determine the prevalence and spectrum of Enterobacteriaceae in 
tracheal aspirate of ventilated children on a PICU. 
(b) to determine the proportion of MDR Enterobacteriaceae in these 
isolates. 
2. to identify risk factors for colonization or infection with MDR 
Enterobacteriaceae in ventilated patients 
3. to identify risk factors for VAP due to Enterobacteriaceae in ventilated 
children 
4. to compare the outcome of VAP due to multi-resistant bacteria to those 
due to sensitive bacteria 
We hypothesize that the outcome (risk of acquiring VAP and risk of death) of 
patients colonized with sensitive Enterobacteriaceae is the same as in patients 
colonized with MDR Enterobacteriaceae.
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2. Methods 
2.1 Patient collective 
The University Children's Hospital Tübingen has a 14-bed PICU. On the ward, 
children with general paediatric, general surgical, neurosurgical and cardio-
surgical problems are cared for. Critically ill children and neonates on this PICU 
are aged between 0 and 18 years, the majority is younger than 5 years. Most of 
them live in Tübingen and surrounding areas, some are admitted from long term 
care facilities or from abroad, e.g. from eastern Europe and Senegal.  
Eligibility criteria 
The patients included in this study were identified from the database of the 
Institute of Medical Microbiology and Hygiene, University of Tübingen. Children 
from 0 to 18 years were included if they were intubated and ventilated through a 
chest tube. Children ventilated through a tracheostoma were excluded. Patients 
meeting the eligibility criteria were included in the study if they had a BAL or a 
tracheal aspirate positive for Enterobacteriaceae. 
2.2 Data collection   
All tracheal aspirates and BAL samples positive for Enterobacteriaceae were 
retrospectively collected from the database of the microbiology laboratory from 
2005-2014 (HyBase Database, Cymed). For every specimen, the individual 
resistance profile was determined by the University Microbiology Laboratory 
according to the clinical breakpoints recommended by the European Committee 
On Antimicrobial Susceptibility Testing (EUCAST) to define susceptibility and 
resistance (58). Medical records of these patients were reviewed. Demographic, 
epidemiological and clinical data as well as treatment and procedures were 
collected from the medical records in the hospital database. All data were 
subsequently aggregated in Excel 2013.  
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2.3 Definitions 
2.3.1 MDR Definition  
International experts of the European Centre for Disease Prevention and Control 
(ECDC) and the CDC propose standardized definitions for multi- (MDR), 
extensive- (XDR), and pan- (PDR) drug resistance in common types of bacteria 
(59).  
Criteria for defining MDR, XDR and PDR in Enterobacteriaceae: 
• MDR: non-susceptible to ≥1 agent in ≥3 antimicrobial categories. 
• XDR: non-susceptible to ≥1 agent in all but ≤2 categories. 
• PDR: non-susceptible to all antimicrobial agents listed. 
In this study the following worksheet by Magiorakos et al. has been used to 
identify MDR organisms (59): 
Antimicrobial categories and agents used to define MDR, XDR and PDR  
Antimicrobial 
category 
Antimicrobial agent Species with intrinsic resistance to 
antimicrobial agents or categories 
Aminoglycosides Gentamicin Providencia rettgeri (P. rettgeri), 
Providencia stuartii (P. stuartii) 
 Tobramycin P. rettgeri, P. stuartii 
 Amikacin   
 Netilmicin P. rettgeri, P. stuartii 
Anti-MRSA 
cephalosporins 
Ceftaroline (approved only 
for Escherichia 
coli,Klebsiella 
pneumoniae,Klebsiella 
oxytoca) 
  
Antipseudomonal 
penicillins +            
β-lactamase 
inhibitors 
Ticarcillin-clavulanic acid Escherichia hermannii (E. hermanii) 
 Piperacillin-tazobactam E. hermanii 
Carbapenems Ertapenem   
 Imipenem   
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 Meropenem   
 Doripenem   
Non-extended 
spectrum 
cephalosporins; 1st 
and 2nd generation 
cephalosporins 
Cefazolin Citrobacter freundii (C. freundii), 
Enterobacter aerogenes (E.aerogenes), 
Enterobacter cloacae (E. cloacae), 
Hafnia alvei (H. alvei), Morganella 
morganii(M. morganii), Proteus penneri 
(P. penneri), Proteus vulgaris (P. 
vulgaris), P. rettgeri, P. stuartii, Serratia 
marcescens (S. marcescens) 
 Cefuroxime M. morganii, P. penneri, P. vulgaris, S. 
marcescens 
Extended-spectrum 
cephalosporins; 
3rd and 4th 
generation 
cephalosporins 
Cefotaxime or ceftriaxone   
 Ceftazidime   
 Cefepime   
Cephamycins Cefoxitin C. freundii, E. aerogenes, E. cloacae, 
H. alvei 
 Cefotetan C. freundii, E. aerogenes, E. cloacae, 
H. alvei 
Fluoroquinolones Ciprofloxacin   
Folate-pathway 
inhibitors 
Trimethoprim-
sulphamethoxazole 
  
Glycylcyclines Tigecycline M. morganii, Proteus mirabilis (P. 
mirabilis), P. penneri, P. vulgaris, P. 
rettgeri,P. stuartii 
Monobactams Aztreonam   
Penicillins Ampicillin Citrobacter koseri (C. koseri), C. 
freundii, E. aerogenes, E. cloacae, E. 
hermanii,H. alvei, Klebsiellae spp., M. 
morganii, P. penneri, P. vulgaris, P. 
rettgeri,P. stuartii, S. marcescens 
Penicillins+               
β-lactamase 
inhibitors 
Amoxicillin-clavulanic acid C. freundii, E. aerogenes, E. cloacae, 
H. alvei, M. morganii, P. rettgeri,P. 
stuartii, S. marcescens 
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 Ampicillin-sulbactam C. freundii, C. koseri, E. aerogenes, E. 
cloacae, H. alvei, P. rettgeri,S. 
marcescens 
Phenicols Chloramphenicol   
Phosphonic acids Fosfomycin   
Polymyxins Colistin M. morganii, P. mirabilis, P. penneri, P. 
vulgaris, P. rettgeri, P. stuartii,S. 
marcescens 
Tetracyclines Tetracycline M. morganii, P. mirabilis, P. penneri, P. 
vulgaris, P. rettgeri, P. stuartii 
 Doxycycline M. morganii, P. penneri, P. vulgaris, P. 
rettgeri, P. stuartii 
 Minocycline M. morganii, P. penneri, P. vulgaris, P. 
rettgeri, P. stuartii 
 
When a species has intrinsic resistance to an antimicrobial agent or to the whole 
category, that agent or category must be removed from the list in this table prior 
to applying the criteria for the definitions and should not be counted when 
calculating the number of agents or categories to which the bacterial isolate is 
non-susceptible (59). 
2.3.2 VAP Definition 
Ventilator-associated pneumonia according to the CDC criteria is defined as: "A 
pneumonia where the patient is on mechanical ventilation for >2 calendar days 
on the date of event, with day of ventilator placement being Day 1, AND the 
ventilator was in place on the date of event or the day before. If the patient is 
admitted or transferred into a facility on a ventilator, the day of admission is 
considered Day 1."  
A patient is defined as ventilated when a mechanical ventilation is performed 
through endotracheal tube or tracheostoma. 
For the diagnosis of pneumonia, the CDC requires different laboratory, clinical 
and radiological criteria depending on the patient collective, based on the 
National Healthcare Safety Networks (NSHN) (34).  
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In this study the following flowchart from the CDC for the diagnosis of pneumonias 
in PICU patients was used.  
                            
    
y.o.=years old, O2 req.=oxygen requirement, WBC=white blood cells 
Source: CDC (34)  
Furthermore, it can be distinguished between early- and late-onset VAP, 
depending on whether the infection occurs within the first 4 days of ventilation or 
afterwards.        
2.4. Microbiology 
Analysis of specimens 
Sputum samples from the lower respiratory tract were collected through deep 
suctioning with the catheter passing beyond the endotracheal tube tip into the 
trachea or bronchi and sent to the University Microbiology Laboratory for routine 
analysis. Analysis was performed according to the local guidelines of the 
University Microbiology Laboratory, laboratory methods have been accredited 
according to DIN EN ISO 15189 and DIN EN ISO/IEC 17025. Organisms were 
grown on agar plates or with liquid culture technique and incubated at 37°C. 
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Monitoring was performed according to the local protocol and fast susceptibility 
testing was realized by rapid disc diffusion technique.  
 
2.5. Statistics  
Analysis of epidemiological data and tables was performed with Excel Version 
2013 for Windows. Patient data were analysed using IBM SPSS Statistics 
Version 22 for Windows.  
To avoid bias due to multiple isolates of one patient, we only used the first isolate 
per patient. Missing data points or data that were not applicable to the analysis 
were excluded.  
Statistical analysis was performed in consultation with the Department of 
Statistics / Biometrics of the University of Tübingen. The categorical variables 
between groups were compared with the [chi]² test. For continuous variables that 
were normally distributed, the means of the two different groups were evaluated 
by two sample unpaired t-test. For continuous variables that were not normally 
distributed, the nonparametric Mann-Whitney-U-Test as well as the Wilcoxon-
Test and the Kruskal-Wallis-Test for comparison between more than two groups 
were used to compare different groups. A p-value <0.05 was considered 
statistically significant. Results are presented as numbers for categorical 
variables. Normally and abnormally distributed quantitative variables are 
presented as mean ± standard deviation and median (minimum and maximum or 
interquartile range), respectively. 
To identify the main risk factors for colonization with MDR Enterobacteriaceae, 
we used a classification and regression tree (CRT) approach and validated the 
findings with the common method of univariate and multivariate logistic 
regression. Many studies have been conducted to identify risk factors for 
colonization with MDR organisms (39,60,61). We selected 10 candidate risk 
factors available in the literature, that are of high relevance in the PICU setting. 
Namely, these risk factors were: patient age, duration of mechanical ventilation, 
duration of placement of a CVL or ECMO, length of stay on PICU prior to tracheal 
aspirate (TA), pre-existing GI-, cardiac or pulmonary disease, days of antibiotic 
pre-exposure, duration of catecholamine therapy. Furthermore the two most 
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prevalent species of Enterobacteriaceae in our study, E.coli and Enterobacter 
were included. All these criteria were analysed in a CRT-model to evaluate their 
impact on the risk of isolation an MDR-strain in the tracheal aspirate of ventilated 
children. 
The CRT approach is a statistical tool to analyse specific subgroups and 
relationships in larger sets of predictor variables that might not be detected with 
more common methods, often used in similar analyses (e.g. multivariable 
regression equations).   
The classification tree was built using SPSS CRT model (IBM SPSS Statistics 
Version 22 for Windows). The algorithm determines a set of predictor variables 
via binary partition, based on statistical significance to create a tree-based 
classification model to predict values of a target variable (dependent) based on 
independent predictor variables. The resulting classification model consists of a 
root node representing the dependent variable and several branches and nodes. 
Each node is assigned to one class representing the most appropriate target 
variable. Finally, the if-then spilt and stop conditions of the most relevant 
candidate predictors result in terminal nodes that provide an accurate prediction 
of the dependent target variable.  
In consideration of the sample size, adequate default values of 19 cases for 
parent nodes and 9 cases for child nodes were chosen. We applied 25-fold cross-
validation to avoid over-fitting and to increase the predictive accuracy of the 
model; maximum tree depth was 5, significance was set at 0.01. Since the CRT 
model is a relatively uncommon statistical method, we used a stepwise validation 
process to validate our findings with the common method of univariate and 
multivariate logistic regression. 
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3. Results  
3.1 Patient characteristics 
Between 2005 and 2014, we found 167 isolates of Enterobacteriaceae in lower 
respiratory tract material of 123 intubated patients on the PICU. 
The patient population consisted of 74 boys (60.2%) and 49 girls, aged from 0 to 
18 years. 17 patients died during their PICU stay or within 6 months after PICU 
admission. Characteristics of the population are shown in Table 1 below. 
Table 1: Demographic and clinical characteristics of 123 intubated patients on 
the PICU.                                                                                                                     
IQR=interquartile range (minimum, maximum), PICU=Paediatric Intensive Care Unit, LOS=length 
of stay 
 
Median [IQR]  
Age (years)  0.5 [0-17.9]  
Gestational age (weeks)  37 [23-42]  
Birthweight (kg)  2.8 [0.6–4.4]  
PICU LOS (days)  14 [1-153]  
 
Admission to the PICU had different reasons, 46% of the patients were 
hospitalized for cardiac surgery. Reasons for admission are shown in Figure 1.  
 
 Figure 1: Reasons for admission to PICU. 
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During their stay on PICU, patients have been diagnosed with various infectious 
diseases, shown in Figure 2. Pneumonia was the most prevalent infectious 
diagnosis (n=64) followed by sepsis (n=40). Urinary tract infections and surgical 
site infections were rare cases. 
 
 
Figure 2: Count of diagnoses.  
Frequency of infectious diseases in the paediatric intensive care unit diagnosed 
during the study period.  
n=number, SIRS=Systemic Inflammatory Response Syndrome 
3.2. Prevalence and spectrum of Enterobacteriaceae  
During the 9-year study period, the number of isolated Enterobacteriaceae in 
lower respiratory tract materials has markedly increased. From 5 positive 
samples in 2005 their number has more than tripled to 17 positive samples in 
2014 with a peak of 27 isolates in 2011. The proportion of MDR organisms 
amongst those Enterobacteriaceae has increased from 0% in 2005 up to 29% in 
2014. 
The incidence of both susceptible and drug resistant gram-negative bacteria in 
the tracheal aspirate of ventilated PICU patients has increased during the study 
period. Figure 3 shows the incidence of Enterobacteriaceae in the lower 
respiratory tract by year. 
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Figure 3:  Incidence per year of susceptible and MDR Enterobacteriaceae in the 
lower respiratory tract material in PICU patients. 
PICU=paediatric intensive care unit, MDR=multidrug resistant 
The overall incidence rate of Enterobacteriaceae has increased from 0.66% in 
2005 to 2.17% in 2014 with a peak of 3.3% in 2011. The MDR incidence rate has 
increased from 0% in 2005 to 0.64% in 2014 with a peak of 1.33% in 2013.  
25 patients had more than one species of Enterobacteriaceae during the same 
hospital stay, (3 out of them had 3, 2 out of them 4 different species). 10 patients 
have either been admitted to PICU and tested positive twice or have been tested 
positive more than 30 days after the first testing, which was defined as a second 
period of infection. 5 Patients had 3 admissions or periods of disease. 
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Regarding the whole study period, the most frequently isolated species were 
Enterobacter spp (n=51) followed by E.coli (n=47) and Klebsiella spp (n=46). The 
distribution of all isolated Enterobacteriaceae is shown in Figure 4. 
 
Figure 4:  Species of all isolates 2005-2014. 
Frequency of isolated Enterobacteriaceae species during the study period. 
spp=species 
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Figure 5: Species 2005. 
Distribution of Enterobacteriaceae species in lower respiratory tract in 2005.  
spp=species 
 
 
Figure 6: Species 2014. 
Distribution of Enterobacteriaceae species in lower respiratory tract in 2014. 
spp=species 
Figure 5 and 6 show a notable shift in the spectrum of Enterobacteriaceae, 
especially E.coli has been isolated more frequently in 2014. 
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3.3 Proportion of drug resistant strains in different Enterobacteriaceae 
subspecies 
All detected bacteria were tested for resistances against antibiotics and classified 
as MDR- and Non-MDR-organisms, following the CDC definition (59). 
 
Figure 7: Susceptible and MDR-isolates. 
Frequency of susceptible and MDR-strains in different Enterobacteriaceae 
species.  
spp=species 
Figure 7 shows the proportion of MDR Enterobacteriaceae species. Morganella 
was found to be the species with the most drug-resistant strains (67%) followed 
by E.coli (55.3%) and Klebsiella spp (28.3%). The total prevalence of MDR-
organisms of all isolated Enterobacteriaceae was 30.5%.   
3.4 ESBL-producing Enterobacteriaceae 
The total proportion of ESBL producing organisms was 13 (7.8%) of all isolates. 
7 out of 47 (14.9%) E.coli and 3 out of 46 (6.5%) Klebsiella spp were ESBL-
producing isolates. 
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3.5 Resistance pattern 
The resistance pattern of the 167 isolates revealed, that 70 % of all 
Enterobacteriaceae were resistant to penicillins and almost 50 % were resistant 
to cephalosporins. However, only 1.8 % of all Enterobacteriaceae were resistant 
to carbapenems.  
 
Figure 8: Resistance profile of all isolates 2005-2014.  
Proportion of Enterobacteriaceae with resistance against different common 
antibiotic agents.  
TMP= Trimethoprim. 
The resistance profiles have changed over the years: while in 2005 and 2006 all 
isolates have been susceptible to carbapenems, in 2013 and 2014 4.9 % were 
resistant. A similar trend can be observed in resistances against 
fluoroquinolones, increasing from 5.9 % in the early study period to 17.1 % in the 
last two years of the study period (see Table 2). Interestingly, resistances against 
cephalosporins have decreased from 64.7 % to 56.1 % while resistances against 
Piperacillin/Tazobactam have increased from 29.4 % to 36.6 % as shown in  
Table 2.  
 
0 10 20 30 40 50 60 70 80 90 100
Piperacillin/Tazobactam
Penicillins
Carbapenems
Fluorochinolones
Aminoglycosides
TMP
Cephalosporins
Resistanceprofile of all isolates 2005-2014
Resistant (%) Susceptible (%)
31 
 
 
Table 2: Resistant strains 2005-2006 and 2013-2014.  
Proportion of resistant strains in isolated Enterobacteriaceae in 2005 and 2006 
compared to those in 2013 and 2014. 
Antibiotic agent Resistant strains (%)  
2005-2006 
Resistant strains (%)  
2013-2014 
Carbapenems 0 4.9 
Fluoroquinolones 5.9 17.1 
Cephalosporins 64.7 56.1 
Piperacillin/Tazobactam 29.4 36.6 
 
3.6 Comparison of characteristics, risk factors and outcome in patients with 
MDR versus patients with susceptible bacteria  
Patients who met the study criteria were younger than the entity of patients 
admitted to PICU. More than half of the study population were infants while only 
about 13% of all PICU patients were younger than one year old. In both 
collectives, boys counted for a little more than half of the population. 
Table 3:  Characteristics of the source population (all patients admitted to PICU 
during the study period) and the study population (a), comparison of patients 
colonized or infected with MDR vs susceptible Enterobacteriaceae (b). 
(a) Characteristics of the source population and the study population  
p=p-value, <0.05 considered significant, n=number, IQR=interquartile range, MDR=multidrug 
resistant, sus=susceptible, m=male, f=female 
 
Source 
population 
(n=7551) 
Study population  
(n=123) 
 
  MDR (n=43) Susceptible 
(n=80) 
p-value 
(MDR vs sus) 
Sex m/f 4129/3422 24/19 50/30 0.47 
Infant/Non-infant 974/6577 25/18 53/27 0.37 
Age in years 
(median, [IQR]) 
3.3 [0.5-10.7] 0.4 [0.1-2.5] 0.6 [0.2-2.0] 0.94 
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The comparison of the MDR vs the non-MDR patient group of the study 
population showed no significant differences for gender distribution or age. 
 
 
(b) Comparison of patients colonized or infected with MDR vs susceptible 
Enterobacteriaceae 
p=p-value, <0.05 considered significant, n=number, IQR=interquartile range, SD=standard 
deviation, MDR=multidrug resistant, BMI=body-mass-index, PICU=paediatric intensive care unit, 
LOS=length of stay, TA=tracheal aspirate, CVL=central venous line, VAP= ventilator-associated 
pneumonia 
Demographic and 
clinical characteristics 
Sensitive 
Entero-
bacteriaceae 
(n=80) 
MDR  
Entero-
bacteriaceae 
(n=43) 
MDR vs 
Sensitive 
(p-value) 
Total 
(n=123) 
Gestational age in 
weeks (median, [IQR]) 
37 [33-39] 37 [34-39] 0.76 37 [34-39] 
Birthweight in kg 
(mean±SD) 
2.67±0.87 2.52±1.05 
 
0.49 2.62±0.93 
BMI (mean±SD; kg/m²) 14.25±3.95 13.65±4.62 0.47 14.02±4.21 
Underlying  
Diseases, n (%) 
    
Pulmonary 40 (50) 25 (58) 0.39 65 (53) 
Cardiosurgical 53 (66) 27 (63) 0.70 80 (65) 
Gastroenterological 35 (44) 26 (61) 0.08 61 (50) 
Neurological 42 (53) 20 (47) 0.53 60 (50) 
Hemato-oncological 7 (9) 3 (7) 0.73 10 (8) 
Immunodeficiency 0 (0) 4 (9) 0.006 4 (3) 
PICU LOS  
(median, [IQR]) 
14.5 [7-32.5] 14 [6-32] 0.89 14 [7-32] 
Days of antibiotic 
therapy prior to TA 
(median, [IQR]) 
2 [0-5] 4 [0-9] 0.2 2 [0-7] 
CVL in place, n (%) 38 (48) 24 (55) 0.48 62 (66) 
CVL days  
(median, [IQR])  
2 [0-7] 
 
3 [0-9] 
 
0.36 2.5 [0-8] 
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VAP incidence, n (%) 10 (13) 9 (21) 0.13 18 (15) 
Days on ventilator 
(median, [IQR]) 
8 [2-16] 6 [3-19] 0.91 7 [3-18] 
All-cause mortality, 
 6 months, n (%) 
9 (11) 8 (20) 0.22 17 (14) 
Source of Table 3 a and b: Renk et al (62) 
Both patient collectives did not differ in gestational age, birthweight and length of 
stay on PICU before and after the testing. Patients with MDR organisms had 
significantly more often an immunodeficiency than the patient group with 
susceptible bacteria.  
Other recorded criteria did not differ significantly between the two groups. 
3.6.1 Risk factors for colonization or infection with MDR Enterobacteriaceae 
in the lower respiratory tract 
We analysed 10 different risk factors for colonization of the lower respiratory tract 
with MDR gram-negative bacteria in a CRT model. 
In our setting, the factors colonization or infection with E.coli, presence of 
gastrointestinal comorbidity and duration of antibiotic exposure prior to tracheal 
aspirate were the most important risk factors. Based on the CRT analysis a model 
to predict the chance of colonization with MDR Enterobacteriaceae was 
generated (Figure 9).   
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Gastrointestinal (GI) comorbidity includes diagnoses such as gastritis, 
gastroenteritis, short bowel syndrome, ileus, liver cirrhosis or -steatosis and other 
liver diseases. 
The CRT model reveals that in our patient population the MDR rate in E.coli 
bacteria is 67% compared to only 22% in non-E.coli bacteria (Node 1 and 2). 
Gastrointestinal comorbidity in combination with an E.coli leads to the highest risk 
(81%) for colonization or infection with an MDR strain (Node 3). On the other 
hand, infection with E.coli without a GI-comorbidity leads to a risk of only 47% for 
the isolation of an MDR organism from tracheal aspirate (Node 4). In non-E.coli 
bacteria, antibiotic exposure of less than 6.5 days leads to a high chance of 88% 
that bacterial isolates are susceptible to antibiotics (Node 6). On the other hand, 
a longer previous antibiotic treatment increases the chance of having a non-E.coli 
organism that is resistant to antibiotics up to 50% (Node 5). Conclusively, in our 
study, GI-comorbidity increased the risk of isolating an MDR E.coli strain in the 
lower respiratory tract, while previous antibiotic exposure increased the risk of 
isolating MDR Enterobacteriaceae other than E.coli . 
Table 4: Risk estimate and classification of MDR and susceptible 
Enterobacteriaceae in tracheal aspirate. Growing method: CRT, dependent 
variable: MDR. 
MDR=multidrug resistant, CRT=Classification and regression tree model 
Observed Predicted 
Susceptible MDR Percent correct 
Susceptible 76 4 95,0% 
MDR 26 17 39,5% 
Overall percentage 82.9% 17.7% 75.6% 
 
As shown in Table 4, the model classifies 75.6% of cases correctly. The model is 
very accurate in predicting susceptible bacteria (95% of cases are predicted 
correctly) while the prediction of MDR strains is correct in only 39.5%. 
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3.6.2 Outcome of MDR infection or colonization vs. non-MDR infection or 
colonization 
The clinical outcome of 123 intubated children colonized with Enterobacteriaceae 
is summarized in Table 5. No significant differences between the two groups were 
found in the duration of mechanical ventilation, the total length of stay on PICU 
or in the death rate. 
 
Table 5: Clinical outcome of children colonized or infected with MDR vs 
susceptible Enterobacteriaceae. 
MDR=multidrug resistant, PICU=paediatric intensive care unit, IQR=interquartile range, p-value 
< 0.05 considered significant 
  MDR (n=43) Susceptible (n=80) p-value 
Days on ventilator 
(median, [IQR]) 
6 [3-19] 8 [2-16] 0.91 
PICU length of stay 
(median, [IQR]) 
14 [6-32] 14.5 [7-32.5] 0.89 
All-cause mortality, 6 
months (% of cases) 
8 (n=20) 9 (n=11) 0.22 
 
3.7 VAP caused by Enterobacteriaceae 
During the study period, 12 girls and 7 boys out of 123 patients colonized by 
Enterobacteriaceae in their lower respiratory tract acquired a VAP during their 
PICU stay. The incidence rate was thus 15.4%. 
Figure 10 shows the increase of VAPs in patients colonized with 
Enterobacteriaceae from 2005 (n=0) to 2014 (n=3) with a peak in 2013 (n=6). 
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Figure 10 : Frequency of VAPs caused by Enterobacteriaceae.  
VAP=ventilator-associated pneumonia 
3.7.1 Distribution of Enterobacteriaceae causing VAP 
As shown in Figure 11, episodes of VAP were mainly caused by Enterobacter 
spp (n=11), less often by E.coli (n=5) and Klebsiella spp (n=3). 
 
Figure 11: Enterobacteriaceae species isolated in patients with VAP. 
VAP=ventilator-associated pneumonia, spp=species 
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Table 6: Comparison of the isolated Enterobacteriaceae species in colonized 
patients to those who actually acquired a VAP.  
spp=species, MDR=multidrug resistant, p=p-value (<0.05 considered significant), 
sus=susceptible. 
Bacterial 
subspecies 
n (% of all 
Enterobacteriaceae) 
n (% of bacterial 
subspecies) 
Colonization sus. 
(n=104) 
Colonization 
MDR (n=31) 
VAP sus. 
(n=10) 
VAP MDR 
(n=9) 
Colon vs. 
VAP 
 p= 
Total susceptible 
(Colon. + VAP) 
Total MDR 
(Colon. + VAP) 
E.coli  
E.coli -  MDR 
30 (24.4) 
18 (45.0) 
5 (4.1) 
4 (10.0) 
0.82 
0.47 
35 (28.5) 
22 (55.0) 
Enterobacter 
Enterobacter- MDR 
31 (25.2) 
2 (5.0) 
11 (8.9) 
4 (10.0) 
0.02 
0.005 
42 (34.1) 
 6 (15.0) 
Klebsiella 
Kelbsiella-MDR 
29 (23.6) 
9 (22.5) 
3 (2.4) 
1 (2.5) 
0.27 
0.27 
32 (26.0) 
10 (25.0) 
Morganella 
Morganella – MDR 
3 (2.4) 
1 (2.5) 
0 (0) 
0 (0) 
0.45 
0.59 
3 (2.4) 
1 (2.5) 
Proteus 
Proteus – MDR 
1 (0.8) 
0 (0) 
0 (0) 
0 (0) 
0.67 
n.a. 
1 (0.8) 
0 (0) 
Others 
Others - MDR 
2 (1.6) 
0 (0) 
0 (0)  
0 (0) 
0.54 
n.a. 
2 (1.6) 
0 (0) 
Serratia 
Serratia – MDR 
6 (4.9) 
1 (2.5) 
0 (0) 
0 (0) 
0.28 
0.59 
6 (4.9) 
1 (2.5) 
Citrobacter 
Citrobacter – MDR 
2 (1.6) 
0 (0) 
0 (0) 
0 (0) 
0.54 
n.a. 
2 (1.6) 
0 (0) 
 
Significant differences (p-value <0.05) were found for Enterobacter spp. 
Enterobacter was significantly more likely to cause a colonization than a VAP 
(p=0.02). MDR Enterobacter on the other hand, were more common in VAP 
patients, while susceptible strains were more often found in colonized patients 
(p=0.05). This trend is especially notable considering the fact that Enterobacter 
spp were the causative organisms for more than 50% of VAP cases in our patient 
population (compare Figure 11). The spectrum of the other Enterobacteriaceae 
did not differ between colonized and VAP-patients. 
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9 out of 19 bacterial stains causing VAP were MDR (47.4%), while the proportion 
of MDR organisms amongst non-VAP patients was only 29.8%. However, this 
difference did not reach significance. 
3.7.2 Clinical aspects of VAP cases 
Most of the patients who developed a VAP were girls (63%, n=12) and had an 
underlying cardiac (89.5%, n=17) and/or respiratory (57.9%, n=11) disease. Most 
patients were younger than one year old.  
5 of these children who had a VAP died on the PICU or in the following 6 months 
after discharge, mostly after a long admission in hospital (median: 31 days, 
maximum: 244 d). Table 7 summarizes a comparison of patients colonized by 
Enterobacteriaceae who developed a VAP vs colonized patients who did not 
develop a VAP.  
Table 7: Characteristics of patients colonized by Enterobacteriaceae and patients 
who developed a VAP caused by Enterobacteriaceae. 
n=number, VAP=ventilator-associated pneumonia, IQR=interquartile range, BMI=body-mass-
index, SD=standard deviation, CVL=central venous line, PICU=paediatric intensive care unit, 
LOS=length of stay, MDR=multidrug resistant, TA=tracheal aspirate, p=p-value (<0.05 
considered significant). 
Demographic and clinical 
characteristics 
Colonized 
(n=104) 
VAP 
 (n=19) 
Colonized 
versus VAP 
(p) 
Total  
(n=123) 
Age (median,[IQR]) 0.5 [0-17.9] 0.4 [0.1-12.6] 0.09 0.45 [0-17.9] 
Age <1 year (%) 59.6 84.2 0.04 63.4 
Sex (female/male, n) 37/67 12/7 0.02 39.8 
Gestational age in weeks 
(median,[IQR]) 
37 [23-42] 37 [27-42] 0.9 37 [23-42] 
BMI (mean±SD; kg/m²) 14.3 ± 4.2 12.7 ± 3.8 0.13 14 ± 4.18 
Underlying disease (% of 
all patients) 
Cardiosurgical 
Gastroenterological 
Neurological 
Hemato-oncological 
 
 
51.2 
44.7 
45.5 
7.3 
 
 
13.8 
4.9 
4.9 
0.8 
 
 
0.02 
0.09 
0.07 
0.6 
 
 
65.0 
49.6 
50.4 
  8.1 
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VAP patients were significantly younger (p=0.04) with an obvious female 
predominance (p=0.02). VAP patients were more likely to have an underlying 
cardio-surgical disease compared to patients that were only colonized with 
Enterobacteriaceae (p=0.02). Furthermore, VAP patients had a longer stay on 
PICU (p=<0,001), duration of antibiotic therapy (p=<0.001), presence of a CVL 
(p=<0.001) and more days on mechanical ventilation (p=<0.001) prior to tracheal 
aspirate. During their stay on PICU, the VAP patients needed a longer time on 
mechanical ventilation (considering both before and after tracheal aspirate) 
(p=<0.001). However, differences in both groups in the total length of stay in the 
hospital, frequency of MDR isolates or in mortality rate did not reach significance.  
 
 
Antibiotic therapy 4 
weeks before TA (% of all 
patients) 
59.6 13.2 0.12 72.8 
Duration of antibiotic 
treatment prior to TA  
(median,[IQR]) 
1 [0-105] 9 [0-73] <0.001 2 [0-105] 
Presence of CVL prior to 
TA (median,[IQR]) 
2 [0-105] 8 [2-111] <0.001 3 [0-111] 
Length of mechanical 
ventilation prior to TA 
(median,[IQR]) 
1 [0-38] 8 [2-34] <0.001 1 [0-38] 
Total length of 
mechanical ventilation 
(median,[IQR]) 
7 [0-93] 19 [5-54] 0.001 7 [0-93] 
PICU LOS prior to TA 
(median,[IQR]) 
1 [0-105] 10 [2-73] <0.001 2 [0-105] 
Total Hospital LOS 
(median,[IQR]) 
29 [1-276] 40 [13-312] 0.06 32 [1-312] 
MDR isolates (n) 31 9  0.13 40  
Mortality rate (% of all 
patients) 
9.9 4.1 0.09 14.0 
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3.7.3 Risk factors for developing a VAP caused by Enterobacteriaceae 
We identified different aspects to be independent risk factors for acquiring a VAP. 
Results of the regression analysis are shown in Table 8. 
Table 8: Simple logistic regression predicting VAP in colonized patients. 
MDR=multidrug resistant, PICU=paediatric intensive care unit, LOS=length of stay, 
ECMO=extracorporeal membrane oxygenation, CVL=central venous line, CI=confidence interval, 
p-value <0.05 considered significant 
 
The simple logistic regression analysis revealed potential risk factors for the 
acquisition of VAP. Amongst these were antibiotic pre-treatment for more than 7 
days, pre-treatment with cephalosporins, a duration of stay on PICU for more 
than 10 days, mechanical ventilation for more than 7 days and ECMO. 
The isolation of an MDR organism from tracheal aspirate did not increase the risk 
for VAP. Interestingly, female patients were at higher risk for VAP. 
Multiple regression analysis showed that pre-treatment with a cephalosporin was 
the risk factor with the highest impact in our study, followed by ECMO and 
mechanical ventilation for more than seven days. However, confidence intervals 
are wide. Results of multiple regression analysis are presented in Table 9. 
 
Risk factor Odds ratio 95% CI p-value 
Sex (female) 3.1 1.13-8.57 0.03 
Birth weight 0.78 0.43-1.43 0.43 
MDR isolate 2.1 0.79-5.73 0.14 
Antibiotic treatment >7 days 10.35 3.03-35.32 <0.001 
Cephalosporin pre-treatment 6.07 1.82-20.25 0.003 
PICU LOS > 10 days 5.34 1.86-15.32 0.002 
Mechanical ventilation >7 days 7.44 2.44-22.74 <0.001 
ECMO 7.14 1.6-31.84 0.01 
CVL >10 days 3.0 0.93-9.71 0.07 
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Table 9: Multiple logistic regression predicting VAP in colonized patients. 
MDR=multidrug resistant, ECMO=extracorporeal membrane oxygenation, CI=confidence 
interval, p-value <0.05 considered significant 
 
3.7.4 Clinical course and outcome of VAPs due to MDR organisms vs VAPs 
due to susceptible organisms 
We compared colonized patients, patients with a VAP caused by sensitive 
bacteria and patients with a VAP caused by an MDR strain. Table 10 summarizes 
the most important results. 
Table 10: Comparison of colonized patients, drug-sensitive VAP patients and 
MDR VAP patients by Kruskal-Wallis test.  
VAP=ventilator-associated pneumonia, MDR=multidrug resistant, CVL=central venous line, 
PICU= paediatric intensive care unit, LOS=length of stay, p-value <0.05 considered significant 
 Colonized 
(n=104) 
VAP sensitive 
(n=10) 
VAP MDR 
(n=9) 
p-value 
Length of mechanical 
ventilation prior to tracheal 
aspirate (median,[IQR]) 
1 [0-38] 5 [2-34] 12 [2-26] <0.001 
Total length of mechanical 
ventilation (median,[IQR]) 
7 [0-93] 18.5 [8-54] 19 [5-45] 0.004 
Presence of CVL prior to 
culture (median,[IQR]) 
2 [0-105] 4 [2-30] 12 [4-111] 0.001 
Risk factor Adjusted 
Odds ratio 
95% CI p-value 
Sex (female) 5.23 1.14-23.93 0.03 
MDR isolate 2.61 0.61-11.12 0.19 
Cephalosporin pre-treatment 11.38 2.07-62.7 0.005 
Mechanical ventilation >7days 7.29 1.61-33.05 0.01 
ECMO 10.6 0.86-130.83 0.07 
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Duration of antibiotic 
treatment prior to tracheal 
aspirate (median,[IQR]) 
1 [0-105] 6 [0-40] 11 [7-73] 0.001 
PICU LOS prior to culture 
(median,[IQR]) 
1 [0-105] 8 [2-40] 12 [2-73] <0.001 
Hospital LOS  
(median,[IQR]) 
29.0 [1-276] 44.5 [13-244] 32 [21-312] 0.13 
 
Children only colonized with Enterobacteriaceae had the shortest duration of 
mechanical ventilation, presence of a CVL, duration of stay on PICU and days of 
antibiotic treatment prior to detection of the gram-negative organism in tracheal 
aspirate. Patients with a VAP caused by susceptible Enterobacteriaceae had a 
significantly longer time on mechanical ventilation, CVL, days on PICU and 
antibiotic pre-exposure. The patient group with VAP caused by MDR 
Enterobacteriaceae had clearly the longest time of mechanical ventilation prior to 
the tracheal aspirate, more than twice as long as the non-MDR VAP group (12d 
vs 5d). Also the presence of a CVL, duration stay on PICU and antibiotic pre-
treatment and were by far the longest in the MDR-VAP group.  
The total length of mechanical ventilation (taking into account days on ventilation 
both before and after the tracheal aspirate) was shortest in the patient group 
colonized only. Both VAP groups had a similar total length of mechanical 
ventilation (non-MDR: 18.5 d, MDR: 19 d) that was a lot higher than in the 
colonized group (1 d).  
No significant differences could be shown between all three groups (no VAP, 
sensitive VAP and MDR VAP) concerning the total length of stay in the hospital.
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4. Discussion  
This study aimed to determine the prevalence and spectrum of 
Enterobacteriaceae isolates in tracheal aspirate of ventilated PICU patients. 123 
patients were included into the study and 167 isolates were analysed. The 
majority of the 123 patients were boys (60.2%), and most were infants (mean age 
6 months). Demographic characteristics of the study population are presented in 
Table 1. Mean duration of PICU stay was 14 days. The main reason for admission 
to PICU was cardiac surgery (46%) or general surgery (28%). During the study 
period, 108 major infections were identified in 123 patients. Pneumonia was most 
prevalent, followed by sepsis. Both diseases are known to be common on PICUs. 
According to the literature, lower respiratory tract infections are responsible for 
25-30% of nosocomial infections on PICUs (63-65).   
4.1 Prevalence and spectrum of Enterobacteriaceae in tracheal aspirate of 
ventilated children  
We analysed the spectrum of Enterobacteriaceae that was detected in the 
tracheal aspirate of intubated PICU patients between 2005 and 2014.  
During the study period, the incidence rate of Enterobacteriaceae has increased 
from 0.66% in 2005 to 2.17% in 2014 with a peak of 3.3% in 2011. The MDR 
incidence rate has increased from 0% in 2005 to 0.64% in 2014 with a peak of 
1.33% in 2013 (see Figure 3). However, these findings might be influenced by 
changing screening policies on the PICU and have therefore a limited value. 
Enterobacter (30.5%), E.coli (28.1%) and Klebsiella (27.5%) were found to be the 
most frequently isolated pathogens in our patient population. The presence of 
these gram-negative bacteria in the lower respiratory tract is mainly explained by 
previous intubation: the placement of an endotracheal tube is quickly followed by 
tracheal colonization with potentially pathogenic organisms from the 
oropharyngeal flora, including MDR organisms (40,41). 
The distribution of Enterobacteriaceae displayed in our study is consistent with 
data from recent research. Wilson et al took daily samples from intubated children 
and found Klebsiella and E.coli as the most common gram-negative isolates, 
followed by Citrobacter freundii and Enterobacter cloacae (40). A prospective 
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study of VAP in PICU patients found Serratia, E.coli and Enterobacter to be the 
most frequent gram-negative organisms cultured from patients with endotracheal 
colonization or VAP (42). Comparisons with data from the literature are difficult 
due to the scarcity of data and differences in study settings. 
Our results show that Enterobacter, E.coli and Klebsiella are common causes for 
endotracheal bacterial colonization in intubated and ventilated PICU patients. 
Therefore, knowledge about resistance patterns of these organisms is crucial to 
adapt empiric treatment guidelines and ensure adequate prevention of PICU 
patients 
4.2 Proportion of drug resistant Enterobacteriaceae 
As drug resistant gram-negative pathogens are an emerging problem worldwide 
(11,16), we analysed the impact of drug resistant Enterobacteriaceae in our study 
population. The overall proportion of MDR organisms in this setting was 30.5% 
of all 167 bacterial isolates. Morganella was the species with the most drug-
resistant strains (67%). However, the informative value of this proportion is limited 
by the small number of only 6 isolated Morganella strains. E.coli was MDR in 
55.3% and Klebsiella spp in 28.3%. Another important observation was the 
increasing importance of MDR organisms, the incidence rate of MDR 
Enterobacteriaceae rose from 0% in 2005 up to 29% in 2014 (Figure 3).  
This result is consistent with the global trend of emerging MDR gram-negative 
organisms. The ECDC reports in its “Antimicrobial resistance annual 
epidemiological report” a “significant increasing trend of combined resistance to 
multiple antibiotics in both E.coli and Klebsiella pneumoniae in more than one 
third of the EU/EEA countries” (66). Similar trends are being reported from the 
U.S. and worldwide (13,67).  
Other studies found MDR rates that differed from our findings: Costa et al. 
reported 46.6% of all gram-negative infections on an oncologic PICU were due 
to MDR organisms between 2009 and 2012 (68). The MDR rate of gram-negative 
organisms causing HAI in a Thai PICU was even higher with 56% (21). Both these 
rates are markedly higher than in our setting. However, the settings are not 
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completely comparable. The differentiation between colonization and infection of 
the respiratory tract is not clearly defined. Our study included colonized patients, 
not just those with infection. Although our data from a single PICU cannot be 
extrapolated and compared to the above mentioned general data, our findings 
are consistent and might reflect these worldwide trends: MDR gram-negative 
organisms are gaining importance and should raise a special concern. 
Surveillance, adapted screening, treatment guidelines and new antibiotic agents 
are needed. 
4.2.1 ESBL-producing Enterobacteriaceae 
ESBL-production is one of the most important mechanisms of resistance in 
Enterobacteriaceae (14). We investigated the frequency of ESBL producing 
strains amongst all isolated bacteria. Our study displayed an overall proportion of 
ESBL-producing organisms of 7.8% in the tracheal aspirate of ventilated PICU 
patients. In E.coli 14.9% of the isolates were ESBL-builders and in Klebsiella spp, 
6.5% of the isolates were ESBL-positive. 
These findings in our setting are consistent with most recent research: studies 
from different settings displayed ESBL-rates between 6.2% and 8.4% for E.coli 
and between 7% and 13.3% for Klebsiella spp (14). A retrospective study from 
2000-2004 reported an ESBL-rate of 7% for both E.coli and Klebsiella in tracheal 
aspirates of PICU-patients in Alabama (69). Other recent studies show higher 
rates of ESBL-building Enterobacteriaceae than our findings: Lee et al. described 
the microbiologic spectrum and susceptibility pattern of clinical isolates from a 
PICU and found a rate of 20% ESBL-positive Klebsiella in 2005 (70).  
Comparability is limited by different patient characteristics and study settings. All 
our patients were mechanically ventilated but did not necessarily have an 
infection. Many other studies only included patients who were clearly diagnosed 
with an infectious disease. 
Generally, the proportion of ESBL-producing Enterobacteriaceae in our study is 
comparable to the available general surveillance data in countries with 
comparable medical standards (14). Though, it is hard to find specific data about 
ESBL-building bacteria in the lower respiratory tract of ventilated children. As 
47 
 
ventilated children are especially vulnerable patients, knowledge about 
epidemiology and prevention of ESBL-building bacteria in children is highly 
important. Further research in this matter is needed, not only concerning ESBL-
building bacteria but MDR gram-negative bacteria in general. 
4.2.2 Carbapenemase-producing Enterobacteriaceae 
Apart from ESBL-production, another important mechanism of drug resistance in 
gram-negative bacteria are carbapenemases. Lately, carbapeneme-resistant 
Enterobacteriaceae (CRE) have been emerging and raise a special concern. 
Both CDC and ECDC report rising rates of carbapenemase-producing Klebsiella 
(11% of HAIs in the US) and E.coli (2%)(11). This trend is especially disturbing, 
keeping in mind that carbapenems are the last line of antibiotics available to treat 
MDR infections. If gram-negative bacteria become resistant to these agents, 
treatment options are severely limited (56). 
The findings in our study setting confirm the reports of CDC and ECDC 
concerning proportion and evolution of carbapenemase-building bacteria. In our 
setting, the overall proportion of carbapenem-resistant bacteria during the nine-
year study period was 1.8% with a notable increase in the later study period 
(Figure 8, Table 2). In the last two years of the study period, 4.9% of all 
Enterobacteriaceae were resistant to carbapenems. This trend is alarming and 
illustrates the urgency for both optimizing prevention and developing new 
treatment strategies.  
4.3 Risk factors for colonization with MDR Enterobacteriaceae in ventilated 
PICU patients 
Knowledge about potential risk factors for colonization or infection with MDR 
Enterobacteriaceae allows the establishment of adequate prevention, screening 
and therapy. Therefore, we identified independent risk factors for isolation of 
MDR organisms in tracheal aspirate in our study population. 
Comparison of patients with MDR bacteria to those with susceptible bacteria 
(Table 3) showed no significant differences in sex, age, gestational age, birth 
weight or body-mass-index (BMI). Regarding comorbidities, underlying 
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immunodeficiencies were more frequent in patients with MDR organisms. 
However, the number of patients suffering from immunodeficiency was very small 
in our study population, so the value of this finding is limited. Gastrointestinal 
comorbidities such as gastritis, gastroenteritis, short bowel syndrome, ileus, liver 
cirrhosis or -steatosis or other liver diseases occurred more often in MDR-
patients, however this difference did not reach significance (p=0.08). Both groups 
showed no significant differences in the presence of other underlying diseases. 
Concerning the clinical course and outcome, the groups showed no differences 
in the duration of antibiotic pre-treatment, days of mechanical ventilation, VAP 
incidence, CVL-days and all-cause mortality over 6 months. 
We investigated several factors available in the literature that could potentially 
increase the risk of colonization with MDR Enterobacteriaceae (21,71). Out of 
these potential risk factors, three were finally identified by the decision and 
regression tree analysis as the most important ones in our setting: 1. colonization 
with E.coli 2. gastrointestinal comorbidity and 3. the duration of antibiotic 
exposure were most relevant for colonization with MDR Enterobacteriaceae 
(Figure 9). 
1.  MDR E.coli raise a special concern: in our setting 55.3% of all detected E.coli 
were drug resistant, the CRT model defined colonization with E.coli as 
independent risk factor for having an MDR organism and the number of isolated 
E.coli has increased over the last years.  
These tendencies are consistent with a large, nationwide study of antibiotic drug 
use and bacterial resistance in the United States and a study from 53 German 
ICUs (72,73). In the latter, the most striking result was the ten-fold increase of 3rd 
generation cephalosporin-resistant E.coli from 2001 to 2008. Highly resistant 
E.coli are known to have a higher infection rate and a higher mortality compared 
to susceptible isolates (74). Keeping this in mind, MDR E.coli should raise 
increased awareness in PICUs. 
2. The second risk factor for colonization or infection with an MDR organism in 
our study was the presence of an underlying gastrointestinal comorbidity. This 
correlation has been described in several publications (71,75). A recent case-
control study from the US, reported that gastrointestinal comorbidities increase 
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the risk for infection at any site with both MDR and susceptible 
Enterobacteriaceae in children (71). It is well known that the stomach is a 
reservoir for gram-negative bacteria, especially in critically ill children or patients 
treated with H2-antagonists that reduce the secretion of gastric acid (76). 
A possible explanation might be the disruption of the physiological 
gastrointestinal flora caused by GI-diseases, surgical procedures or selection by 
antibiotic treatment. The disturbed bacterial flora can lead to an overgrowth of 
non-physiological, potentially drug-resistant bacteria. These bacteria might now 
be transported into the lower respiratory tract by gastroesophageal reflux and 
micro-aspiration or colonization of the upper pharynx and subsequent tracheal 
colonization after intubation (76).  
Furthermore, health care workers might transport GI-bacteria into the respiratory 
tract e.g. when handling a PEG (percutaneous endoscopic gastrostomy) or 
during tracheal suctioning without sufficient hygiene measures. 
3. The third risk factor detected by the CRT model was the duration of antibiotic 
treatment prior to the detection of drug resistant Enterobacteriaceae. It is well 
known that antibiotic treatment leads to a suppression of both physiological and 
pathogenic bacteria, favouring those strains that are resistant to the antibiotic 
agent and finally lead to overgrowth of these resistant bacteria (11,25). Therefore, 
it is not surprising that a longer duration of antibiotic treatment increases the risk 
of infection or colonization by MDR Enterobacteriaceae. In our study setting, the 
critical length of antibiotic treatment that increased the risk of infection with MDR 
bacteria was 6.5 days. Most studies agree that antibiotic exposure, especially 
pre-treatment with broad spectrum antibiotics, increases the risk of MDR-
acquisition (21,23,25).  A Chinese study reports, that administration of 3rd 
generation cephalosporins is an independent risk factor for infection with ESBL-
producing bacteria (77). Unfortunately, mostly there is no specification 
concerning a cut-off or a critical length of the antibiotic treatment. Tamma et. al 
conducted a retrospective study to investigate the antibiotic treatment of 
ventilator-associated tracheitis in children. The patient group who received an 
antibiotic treatment for more than 7 days had a higher risk for an MDR organism 
in the lower respiratory tract than the patient group that was treated for a shorter 
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period (78). These findings correspond well with our cut-off of 6.5 days. More 
research is needed, to specify the critical length of antibiotic treatment that 
increases the risk of MDR acquisition. 
The risk factors for isolation of MDR Enterobacteriaceae that we found in our 
study facilitate the identification of children at risk for colonization and infection 
with MDR organisms. This could potentially lead to adaption of empiric antibiotic 
treatment and consequently decrease the risk of MDR-acquisition. Mechanically 
ventilated children who have an E.coli in the tracheal aspirate and children who 
suffer from gastrointestinal comorbidities should be watched carefully for 
appearance of multidrug resistant bacteria. Antibiotic treatment should be kept as 
short as possible to avoid an increased risk for acquiring an MDR organism. 
 
4.4 Outcome of colonization or infection with MDR organisms 
Many studies show, that MDR organisms can worsen clinical outcomes 
compared to colonization or infection with susceptible strains. This might include 
longer duration of ventilation, longer duration of stay in the hospital or higher 
morbidity with consequently elevated healthcare costs (11,12,74,79). MDR 
organisms commonly do not feature higher pathogenicity than their more 
susceptible counterparts of the same genera. However, MDR organisms are 
known to increase mortality due to delayed or inappropriate antibiotic 
therapy (74,80). 
In this study, we investigated whether patients colonized with MDR organisms 
had more ventilation days in total, a longer stay on PICU or a higher rate of death. 
In this setting, the overall outcome was similar in both groups (Table 5). 
In our institution, susceptibility testing is rapidly available and empiric antibiotic 
therapy is rather aggressive. Rapid targeted therapy might be the explanation 
that differences in outcome and mortality have not been observed in our study. 
Additionally, differences in ventilation days, length of PICU stay and mortality may 
hardly be detected in our study, which was based on a low number of cases and 
included PICU patients with a vast variability in comorbidities and severity of 
diseases. 
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4.5 Enterobacteriaceae causing VAP on PICU 
Ventilated PICU patients, as in our study setting, are at a special risk for acquiring 
VAP. Enterobacteriaceae are a major cause for these VAP (4,81) and MDR gram-
negative organisms are becoming increasingly relevant in the PICU setting 
(4,42). Against this background, we investigated the distribution and proportion 
of drug-resistant Enterobacteriaceae in the patients who had a VAP. 
Furthermore, we determined risk factors and outcome of VAP in our patient 
population. 
4.5.1 Distribution of Enterobacteriaceae subspecies causing VAP 
Gram-negative bacteria, especially P.aeruginosa, are the main cause for VAP on 
PICUs. Gram-positive rods such as S.aureus are also common in VAP patients, 
but not as frequently isolated as gram-negative strains (4,42,82). As 
Enterobacteriaceae are a major part of the gram-negative bacteria, we took a 
closer look on the distribution of bacterial subspecies in VAP patients of our 
patient population. 
Episodes of VAP were mainly caused by Enterobacter, less often by E.coli and 
Klebsiella (Figure 11). This is not surprising, keeping in mind that these three 
subspecies were by far the most common ones in our setting. A prospective study 
of VAP in children displayed a comparable spectrum of Enterobacteriaceae as 
causative organisms for VAP: Srinivasan et al. found gram-negative organisms 
to be the causative organisms for 42% of all VAPs with E.coli being the 
predominant gram-negative organism followed by Enterobacter spp and Serratia 
spp (42). In our setting, MDR organisms were found more often in VAP than in 
non-VAP patients. Almost half of the VAPs (47.4%) were caused by MDR 
Enterobacteriaceae (Table 6). However, this difference did not reach 
significance, possibly due to the small number of cases. 
The high proportion of MDR organisms causing VAP that we observed, reflects 
the increasing relevance of MDR Enterobacteriaceae on PICUs (4,42). A 
multinational study displayed that 37,5% of all Klebsiella causing nosocomial 
infections on PICUs were MDR. Furthermore, the authors pointed out that the 
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amount of MDR organisms had increased towards the end of the study  
period (83).  
In our study setting, the number of VAP cases caused by MDR 
Enterobacteriaceae is too small to draw conclusions about a general tendency 
whether MDR gram-negative bacteria are increasingly responsible for VAP on 
PICU. Although, given the high percentage of MDR-caused VAPs in our study 
and the reports from other PICUs, this question seems to be an important one 
and should be investigated in further research. 
Furthermore, we investigated whether the distribution of bacterial subspecies and 
the proportion of drug resistant strains differed between patients who acquired a 
VAP and patients who were only colonized (Table 6). 
We found that Enterobacter spp were significantly more likely to cause a 
colonization than a VAP (p=0.02). But interestingly, MDR Enterobacter spp were 
more common in VAP patients, while susceptible strains were more often found 
in colonized patients (p=0.05). Considering the fact that Enterobacter spp were 
the causative organisms for more than 50% of VAP cases in our patient 
population (Figure 11), these findings are especially notable. Whenever the 
diagnosis of a VAP seems probable, MDR Enterobacter should be kept in mind 
in matters of diagnosis and empiric therapy.  
Finally, it has to be mentioned that all our findings concerning VAP caused by 
Enterobacteriaceae are based on isolation of these bacteria in tracheal aspirates. 
Some authors criticise, that this method is not accurate enough and can lead to 
over-diagnosis (40,55). Nevertheless, the S-3 guidelines for diagnosis of VAP in 
adults recommends non-invasive procedures such as tracheal aspirate instead 
of more invasive procedures like BAL or even lung biopsy (53). Summing up, 
isolation of specific pathogens in tracheal aspirate in combination with clinical 
findings are widely accepted for the diagnosis of VAP (34,84).  In our study, we 
followed this approach and defined only children who fulfilled both microbiological 
and clinical criteria as VAP patients. 
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4.5.2 Characteristics of patients with VAP 
19 out of 123 patients included in the study acquired a VAP during their hospital 
stay, the VAP rate during the study was thus 15.4%.  
Most authors report a female predominance in VAP patients (32,85), our findings 
with a female/male ratio of 12:7 (coming from a patient population with 60% boys) 
and female sex being an independent risk factor for VAP are in accordance with 
these data. 
VAP patients were significantly younger and more likely to have an underlying 
cardiac disease compared to patients who did not acquire a VAP. They had a 
longer stay on PICU and more days on mechanical ventilation before being 
diagnosed with VAP, with longer previous antibiotic therapy and previous 
presence of a CVL than non-VAP patients (Table 7). 
Even though many studies show that VAP can lead to a longer hospital length of 
stay and higher mortality (30,42), VAP patients did not have a significantly longer 
total PICU length of stay or a higher mortality rate in our setting.  
Interestingly the frequency of VAPs caused by Enterobacteriaceae increased 
over the study period while patient admissions stayed on a stable level (Figure 
10). Keeping in mind the increasing amount of MDR organisms amongst 
Enterobacteriaceae (86,87), this trend should be observed closely.  
4.5.3 Risk factors for acquiring VAP caused by Enterobacteriaceae on PICU 
Knowledge about risk factors is important to optimize prevention and diagnosis 
of VAP. In our setting, antibiotic pre-treatment for more than 7 days, pre-treatment 
with cephalosporins, a stay on PICU for more than 10 days, mechanical 
ventilation for more than 7 days and being on ECMO have significantly increased 
the risk of VAP acquisition (Table 8 and 9). Most of the risk factors identified from 
our patient collective have been described as independent risk factors for VAP in 
studies from other settings. 
The most important way of acquiring a VAP is the contamination of the lower 
respiratory tract by bacteria of the oro- or nasopharynx that happens during 
intubation (88). Antibiotic pre-treatment disturbs this endogenous oro- and 
nasopharyngeal flora and facilitates the colonization with nosocomial and 
54 
 
potentially drug resistant bacteria. Many studies have shown that antibiotic pre-
treatment increases the risk of VAP in both children and adults (41,89,90).  
When we tested all antibiotics independently on their impact on VAP-acquisition, 
only cephalosporins were found to be an independent risk factor for VAP. This 
finding might be due to the fact that cephalosporins were by far the most 
commonly used class of antibiotics in out setting and had thus a higher influence 
than the other antibiotics. Furthermore, cephalosporins are known to increase the 
risk of acquiring an MDR gram-negative organisms and can facilitate nosocomial 
infections as VAP (91). 
 A long stay on NICU/PICU and prolonged mechanical ventilation are further 
important risk factors described in many studies about VAP (49,51,89). This is 
reasonable, as a longer stay in the hospital means a longer exposure to 
nosocomial bacteria and a longer time of placement of the endotracheal tube 
means more chances of micro-aspirations and following VAP (51). 
In the literature, many more risk factors for VAP such as re-intubation or enteral 
feeding are described (30,51). We could not investigate all these risk factors in 
our study. 
Our study setting only includes ventilated PICU patients, and therefore a 
preselected patient population of ventilated children with Enterobacteriaceae in 
the tracheal aspirate. The findings about risk factors and outcome of VAPs 
consequently cannot be applied to all PICU patients. 
General consequences can be drawn from these data. Antibiotic treatment, 
especially with cephalosporins, as well as mechanical ventilation should be used 
as restrictively as possible. If a child needs a prolonged treatment requiring the 
above mentioned risk factors, physicians should be aware of the risk for VAP 
caused by Enterobacteriaceae. This applies especially to girls, who are at a 
higher risk for VAP.  
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4.5.4 Clinical course and outcome of patients with MDR VAP 
Finally, we analysed if the presence of an MDR organism had an impact on the 
clinical course of VAP (Table 10). We compared patients with VAP due to an 
MDR bacterium to both patients with VAP due to a susceptible organism and to 
patients colonized with Enterobacteriaceae without VAP. We evaluated different 
aspects that can be divided in (a) clinical course and interventions prior to the 
detection of Enterobacteriaceae in the tracheal aspirate and (b) clinical outcome, 
taking into account the time both before and after the diagnosis of VAP. 
(a)  Patients with VAP due to an MDR bacterium had a significantly longer 
duration of mechanical ventilation prior to the detection of a gram-negative 
organism in the tracheal aspirate than VAPs caused by a sensitive bacterial 
strain. Furthermore, MDR VAPs had a longer presence of a CVL, stay on PICU 
and more days on antibiotic treatment prior to the tracheal aspirate. Patients who 
did not have a VAP but were only colonized had a shorter duration of all the 
above-mentioned factors.  
The three groups showed significant differences in aspects that are known to be 
risk factors for the acquisition of VAP: days on mechanical ventilation, presence 
of a CVL, days on PICU and previous antibiotic treatment. The two VAP groups 
(MDR and non-MDR) had a significantly longer exposure towards these risk 
factors than the non-VAP group. Furthermore, it seems that a prolonged 
exposure towards the risk factors increases the risk that the VAP is caused by 
MDR strains. This tendency appears to be important and should be investigated 
in further research.   
(b)  MDR organisms are known to be a cause for delayed adequate antibiotic 
treatment (24,68). For this reason, a worse outcome in patients with MDR 
organisms, including prolonged mechanical ventilation, a prolonged stay on PICU 
and a higher mortality could be expected. These tendencies have been reported 
in several studies (24,79,80), even though data from comparable study settings 
are rare. However, we could not confirm all of the mentioned expectations in our 
study: no significant differences could be shown between MDR VAPs, sensitive 
VAPs and colonized patients concerning the total length of stay in the hospital. 
The total length of mechanical ventilation was longer in the in VAP-patients than 
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in non-VAP patients, but the MDR-status of the bacteria that caused VAP did not 
have a significant influence. 
Given that our setting included only 9 patients suffering from VAP due to MDR 
Enterobacteriaceae, these findings have to be treated with caution. Significant 
differences might not be detected in such small groups. Keeping in mind that 
VAPs are amongst the most important nosocomial infections on PICU and that 
MDR gram-negative organisms are becoming increasingly relevant as a cause 
for VAP, more research is needed to assess the impact of drug resistance on 
clinical course and outcome in PICU patients suffering from VAP.
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Summary 
MDR gram-negative bacteria are an emerging problem in Germany and 
worldwide. The family of Enterobacteriaceae in particular is a common cause for 
various nosocomial infections. One important way of acquiring nosocomial 
bacteria is endotracheal intubation, during which potentially drug resistant 
bacteria can be transported into the lower respiratory tract and eventually cause 
severe infections such as ventilator-associated pneumonia (VAP). 
Against this background, we conducted a retrospective single-centre study to 
investigate the epidemiology of Enterobacteriaceae in tracheal aspirate of 123 
ventilated PICU (paediatric intensive care unit) patients between 2005 and 2014. 
The study aimed to describe the frequency, distribution and resistance-status of 
Enterobacteriaceae in the lower respiratory tract of ventilated PICU patients; to 
identify risk factors and to analyse the clinical outcome of endotracheal 
colonization or infection with multidrug resistant Enterobacteriaceae. 
Furthermore, we identified patients who had a VAP due to Enterobacteriaceae 
and investigated risk factors and outcome with special attention to VAPs caused 
by MDR bacteria. 
A total of 167 isolates of Enterobacteriaceae were detected in the tracheal 
aspirate of 123 patients. The most frequently isolated species were Enterobacter 
spp, E.coli and Klebsiella spp with an  overall MDR-proportion of 30.5%. Both 
incidence of Enterobacteriaceae and proportion of MDR organisms have 
markedly increased over the study period. Analysis by a CRT model revealed, 
that colonization or infection with E.coli, presence of gastrointestinal comorbidity 
and antibiotic exposure of more than 6.5 days prior to tracheal aspirate were the 
most important independent risk factors for isolation of MDR Enterobacteriaceae 
in the tracheal aspirate. Clinical outcome did not differ between MDR and non-
MDR patients. 
19 of the patients included in the study acquired a VAP, mostly caused by 
Enterobacter spp. VAP patients were younger, with a higher proportion of females 
compared to males. The most important risk factors for VAP were prolonged stay 
on PICU, mechanical ventilation and antibiotic pre-treatment. 47.4% of the VAPs 
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were MDR, however, the MDR-status of the causative organism did not affect the 
clinical outcome of the VAP. The number of VAPs is too small to draw a final 
conclusion about risk factors and impact of MDR Enterobacteriaceae causing 
VAP on PICU.  
The trend of emerging MDR gram-negative organisms in the PICU setting should 
raise increased awareness. Surveillance, adapted screening- and treatment 
guidelines as well as new antibiotic agents are needed. Furthermore, the 
possibility of a respiratory tract infection caused by potentially drug resistant 
Enterobacteriaceae should be kept in mind whenever a child is on mechanical 
ventilation.  
The subject of VAP caused by MDR Enterobacteriaceae on PICU is not yet well 
investigated and more research is needed to assess epidemiology, risk factors 
and treatment options. 
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Zusammenfassung 
Nosokomiale Infektionen werden häufig durch gramnegative Bakterien, 
insbesondere durch Enterobacteriaceae, ausgelöst. Leider zeichnete sich in den 
letzten Jahren in Deutschland und weltweit eine deutliche Zunahme an 
Antibiotikaresistenzen bei dieser Erregergruppe ab. Eine nosokomiale Infektion 
durch multiresistente Enterobacteriaceae birgt das Risiko vermehrter 
Komplikationen und eines schlechteren Outcomes, da die empirische 
Antibiotikatherapie nicht greift und eine adäquate antibiotische Therapie häufig 
erst verzögert eingesetzt wird. Da Kinder, insbesondere Säuglinge und 
Intensivpatienten, ein erhöhtes Risiko für nosokomiale Infektionen haben, wurde 
in dieser retrospektiven Studie die Epidemiologie von Enterobacteriaceae im 
Trachealsekret beatmeter Kinder auf der pädiatrischen Intensivstation der 
Universitätsklinik Tübingen untersucht.  
Die Studie hatte folgende Ziele: 
1. (a) Bestimmung der Prävalenz und des Spektrums von Enterobacteriaceae 
im Trachealsekret beatmeter Kinder 
(b) Bestimmung des Anteils an multiresistenten Bakterien in den Isolaten 
2.  Identifikation von Risikofaktoren für endotracheale Besiedlung oder Infektion   
durch multiresistente Enterobacteriaceae  
3. Vergleich des Outcomes von Patienten mit sensiblen Keimen gegenüber 
Patienten mit multiresistenten Keimen 
3. Identifikation von Risikofaktoren für beatmungsassoziierte Pneumonien bei 
Kindern mit endotrachealer Besiedlung durch Enterobacteriaceae 
 
Ergebnisse: Es wurden retrospektiv alle Patienten identifiziert, in deren 
Trachealsekret zwischen 2005 und 2014 Enterobacteriaceae nachgewiesen 
wurden. Insgesamt wurden 167 Isolate von 123 Patienten ausgewertet. Die am 
häufigsten isolierten Gattungen waren dabei Enterobacter spp, E.coli und 
Klebsiella spp mit einem Anteil an multiresistenten Keimen von insgesamt 30.5%. 
Sowohl die Inzidenz von Enterobacteriaceae im Trachealsekret als auch der 
Anteil resistenter Keime stiegen im Verlauf der Studie deutlich an.  
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Die statistische Analyse mittels CRT Model ergab, dass endotracheale 
Besiedlung und Infektion durch E.coli, gastrointestinale Komorbiditäten sowie 
antibiotische Vorbehandlung von mehr als 6.5 Tagen vor der Entnahme des 
Trachealsekrets unabhängige Risikofaktoren für eine endotracheale Besiedlung 
oder Infektion durch multiresistente Enterobacteriaceae darstellten. In diesem 
Setting unterschied sich das klinische Outcome von Patienten mit resistenten 
Erregern nicht signifikant vom Outcome der Patienten mit sensiblen Erregern. 
19 Patienten erfüllten die Kriterien einer beatmungsassoziierten Pneumonie 
(ventilator-associated pneumonia, VAP). 58% dieser VAPs wurden durch 
Enterobacter spp hervorgerufen. Die VAP-Patienten waren signifikant jünger und 
häufiger weiblich als die Gesamtheit der Patienten. Unabhängige Risikofaktoren 
für eine VAP bei Kindern mit Enterobacteriaceae im Trachealsekret waren ein 
langer Aufenthalt auf der Intensivstation, eine lange Beatmungsdauer und eine 
lange antibiotische Vorbehandlung. 47% der beatmungsassoziierten 
Pneumonien wurden durch multiresistente Erreger ausgelöst, das klinische 
Outcome änderte sich dadurch jedoch nicht. Aufgrund der geringen Zahl an VAPs 
sind diese Ergebnisse allerdings nur eingeschränkt verwertbar. 
 
Fazit: Die in vielen Studien beschriebene steigende Inzidenz multiresistenter 
gramnegativer Erreger ließ sich auch in unserem Setting beobachten. Diese 
Entwicklung ist besorgniserregend und erfordert adäquate Screening- und 
Behandlungsschemata. Im klinischen Alltag sollte bei allen intubiert beatmeten 
Kindern die Möglichkeit einer endotrachealen Besiedlung durch multiresistente 
Enterobacteriaceae berücksichtigt werden. Dies gilt insbesondere bei 
Vorhandensein von entsprechenden Risikofaktoren, wie endotrachealer 
Besiedlung durch E.coli oder gastrointestinaler Komorbiditäten. Antibiotika 
sollten so restriktiv wie möglich eingesetzt werden, um einer Entwicklung von 
Resistenzen bei endotrachealer bakterieller Besiedlung vorzubeugen. 
Die Datenlage zu beatmungsassoziierte Pneumonien durch multiresistente 
Enterobacteriaceae im pädiatrischen Setting ist derzeit nicht ausreichend und 
erfordert weitere Forschung.
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